梅花生物: 梅花生物关于跨境收购业务与资产的进展公告

Group 1 - The company has signed a share and asset purchase agreement with Kirin Holdings' subsidiary to acquire certain businesses for 10.5 billion JPY (approximately 500 million CNY) [1] - The acquisition includes food amino acids, pharmaceutical amino acids, and human milk oligosaccharides (HMO) [1] - The final transaction price is approximately 16.8 billion JPY (about 833 million CNY) after adjustments based on cash reserves and working capital [2] Group 2 - The business transfer was completed on July 1, 2025, with all conditions of the agreement met [2] - As of June 30, 2025, the estimated cash on hand for the acquired assets was approximately 11.3 billion JPY (about 560 million CNY) [2] - The company will continue to monitor the progress of the acquisition and provide timely updates as required [2]